We’ve recently released an Initiation of Coverage Report on Faron Pharmaceuticals. Faron is a clinical stage drug development company focused on immunology. The lead candidate bexmarilimab is an immuno oncology drug developed for various solid tumors and blood cancers. The full report is availabe to all readers freely. Feel free to ask any questions you may have on the investment case and please remember to tag my name to avoid missing your question.
-Antti, Analyst, Life Sciences